Supplies it“Provides computational biologists, bioinformaticians, clinical trial managers, and regulatory affairs specialists with domain intelligence built into frontier models across organic chemistry, structural biology, lab protocols, and bioinformatics pipelines.”
Latest 424B4final IPO prospectusMixedControlled company ·
Sells Claude AI models and coding tools; $81.3B offering funds compute expansion
Sells it 92%, $3.2B a year“We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels.”
Weak BioSpin and NANO demand, tariffs and impairments overwhelmed CALID growth; Bruker is restructuring to restore margins.
Revenue$3.4BYoY +2.1%
Net income−$8.6Mvs $113.1M year ago
Latest 10-QQ3 FY2026Impairment / charge ·
Competition and weak BSB&CA performance erase its remaining goodwill, while cost savings and product mix lift margins.
Revenue$874.0MYoY +1.6%
Net income−$111.8MYoY −87.6%
Latest 8-KLeadership change ·
Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.
Latest 8-KInvestor update ·
BioSpin and CALID divisions reorganized into BIOS and new BMID to sharpen accountability; historical segment results recast without changing consolidated results.
Sells it 13%, $48.4M a year“We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a solid organ or stem cell donor and a recipient, and help provide post-transplant surveillance.”
Latest 10-KFY2025Mixed ·
Pharmacy and Ottr expansion drive growth beyond testing, while reimbursement and collection adjustments limit revenue per test.
Revenue$379.8MYoY +13.8%
Net income−$21.4Mvs $52.5M year ago
Latest 10-QQ3 FY2026Positive ·
Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.
Revenue$139.4MYoY +39.3%
Net income$19.3Mvs $1.7M year ago
Latest 8-KPositiveEarningsGuidance raised ·
Testing Services growth, including NavDx oncology, fuels higher FY2026 revenue guidance of $520M–$530M.
Latest 8-KPositiveDeal completed ·
Sold Lab Products to Eurobio for $171.7M and acquired Naveris for $161.8M upfront, adding NavDx specialty oncology testing.
Latest 8-KExecutive payShareholder vote ·
Stockholders approved adding 1.6M shares to the 2024 Equity Incentive Plan reserve.
Supplies it, part of Industrial Segment“Applications within the biotechnology segment include research and diagnostic tools such as flow cytometry, genome sequencing, and PCR, to name a few.”
Latest 10-KFY2026Mixed ·
AI optics demand drives growth; NVIDIA-backed indium phosphide expansion and inventory buildup drain cash.
Revenue$7.1BYoY +22.5%
Net income$805.0Mvs $49.4M year ago
Latest 10-QQ1 FY2027Positive ·
AI optical demand drives NVIDIA-backed indium phosphide expansion, but inventory buildup turns operating cash flow negative.
Revenue$2.4BYoY +49.9%
Net income$384.7MYoY +69.9%
Latest 8-KPositiveBuyback ·
Authorized up to $2.0B in share repurchases through open-market trades, negotiated deals or derivatives.
Latest 8-KPositiveEarningsGuidance raised ·
PhotonLink secures a ≈$20B five-year agreement as AI datacenters shift to optics; revenue ramp expected in Q4 CY2026.
Latest 8-KExecutive pay ·
Special performance-stock awards for James Anderson and four executives target retention, with payouts tied to four-year share-price and relative-return hurdles.
Sells it 36%, $16.1B a year“Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease.”
Latest 10-KFY2025Restructuring ·
Solventum filtration purchase and pending Clario deal deepen the push into drug development and production as academic demand and China sales weaken.
Sells it 100%, $459.4M a year“We have developed multiple products and solutions derived from synthetic DNA and our versatile DNA synthesis technology.”
Latest 10-KFY2026Positive ·
AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.
Revenue$459.4MYoY +22.0%
Net income−$130.2MYoY −67.6%
Latest 10-QQ3 FY2026Legal / investigation ·
Synthetic biology and therapeutics demand drove growth, but commercial and infrastructure spending widened operating losses.